Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 09, 2016 11:05 AM ET


Company Overview of Applied Genetic Technologies Corporation

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products to treat patients with severe inherited orphan diseases in ophthalmology in the United States. The company’s lead product candidates include treatments for X-linked retinoschisis, achromatopsia, and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye caused by mutations in single genes. It is also developing adeno-associated virus based gene therapies for the treatment of rare eye diseases; and a product candidate for treatment of alpha-1 antitrypsin deficiency for which it has conducted preclinical proof-of-concept studies and Phase I and Phase II clinic...

11801 Research Drive

Suite D

Alachua, FL 32615

United States

Founded in 1999

35 Employees



Key Executives for Applied Genetic Technologies Corporation

Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $400.0K
Chief Financial Officer
Age: 59
Total Annual Compensation: $300.0K
Chief Medical Officer and Vice President
Age: 68
Total Annual Compensation: $350.0K
Chief Business Officer and Vice President
Age: 59
Total Annual Compensation: $127.1K
Chief Scientific Officer
Age: 55
Total Annual Compensation: $79.2K
Compensation as of Fiscal Year 2015.

Applied Genetic Technologies Corporation Key Developments

Applied Genetic Technologies Corporation Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2015

Applied Genetic Technologies Corporation reported unaudited earnings results for the second quarter and six months ended December 31, 2015. For the quarter, the company reported total revenue of $12,189,000 against $652,000 a year ago. Income from operations was $2,870,000 against loss from operations of $4,702,000 a year ago. Net income was $3,045,000 or $0.17 per basic and diluted share against net loss of $4,650,000 or $0.28 per basic and diluted share a year ago. For the six months, the company reported total revenue of $23,251,000 against $1,357,000 a year ago. Loss from operations was $6,343,000 against $10,111,000 a year ago. Net loss was $6,078,000 or $0.35 per basic and diluted share against $10,031,000 or $0.63 per basic and diluted share a year ago.

Applied Genetic Technologies Corporation, Q2 2016 Earnings Call, Feb 08, 2016

Applied Genetic Technologies Corporation, Q2 2016 Earnings Call, Feb 08, 2016

Applied Genetic Technologies Corporation to Report Q2, 2016 Results on Feb 08, 2016

Applied Genetic Technologies Corporation announced that they will report Q2, 2016 results at 5:00 PM, Eastern Standard Time on Feb 08, 2016

Similar Private Companies By Industry

Company Name Region
VisiGen Biotechnologies, Inc. United States
Technologene Inc. United States
Sagres Discovery, Inc. United States
Adaptive Symbiotic Technologies LLC United States
Percival Scientific Incorporated United States

Recent Private Companies Transactions

Private Placement
July 2, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Applied Genetic Technologies Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at